Provided by Tiger Trade Technology Pte. Ltd.

TG Therapeutics

53.34
+0.39000.74%
Pre-market: 53.340.00000.00%07:44 EDT
Volume:1.74M
Turnover:92.10M
Market Cap:8.17B
PE:19.26
High:53.90
Open:53.34
Low:52.12
Close:52.95
52wk High:59.30
52wk Low:26.76
Shares:153.09M
Float Shares:141.54M
Volume Ratio:0.94
T/O Rate:1.23%
Dividend:- -
Dividend Rate:- -
EPS(TTM):2.77
EPS(LYR):2.77
ROE:100.28%
ROA:7.28%
PB:13.52
PE(LYR):19.26

Loading ...

TG Therapeutics Announces Initiation of Phase 2 Trial Evaluating Briumvi in Patients with Treatment-resistant Schizophrenia

THOMSON REUTERS
·
Jul 06

TG Therapeutics (TGTX) Gains Momentum As The Fair Value Narrative Turns More Cautious

Simply Wall St.
·
Jun 26

TG Therapeutics price target raised to $83 from $57 at Jefferies

TIPRANKS
·
Jun 23

Movement Alert|TG Therapeutics Rises 6.88% in Regular Trading, Trading at $56.5

Market Focus
·
Jun 22

Jefferies Reaffirms Their Buy Rating on TG Therapeutics (TGTX)

TIPRANKS
·
Jun 22

TG Therapeutics Stock Rises Thursday: What's Driving The Gains?

Benzinga_recent_news
·
Jun 19

TG Therapeutics Shareholders Reject Executive Compensation at Meeting

TIPRANKS
·
Jun 13

TG Therapeutics shareholders reject executive pay proposal at annual meeting

Reuters
·
Jun 13

A Look At TG Therapeutics (TGTX) Valuation After Fresh BRIUMVI Clinical And Formulation Milestones

Simply Wall St.
·
Jun 10

BUZZ-U.S. STOCKS ON THE MOVE-Cleveland-Cliffs, Ciena Corp, Nokia Oyj

Reuters
·
Jun 09

TG Therapeutics: Buy Rating Reiterated on Briumvi Expansion Strategy, $70 Price Target Unchanged

TIPRANKS
·
Jun 09

BUZZ-U.S. STOCKS ON THE MOVE-Toll Brothers, TG Therapeutics, CECO Environmental

Reuters
·
Jun 09

BUZZ-TG Therapeutics rises as early-stage data shows benefit in rare muscle weakness disease

Reuters
·
Jun 09

TG Therapeutics launches Phase 2 trial testing Briumvi maintenance after efgartigimod in myasthenia gravis

Reuters
·
Jun 09

TG Therapeutics - Subcutaneous Briumvi Generally Well Tolerated With Safety Profile Consistent With Iv Formulation

THOMSON REUTERS
·
Jun 09

TG Therapeutics Announces Positive Topline Phase 1 Data for Subcutaneous Briumvi in Patients With Myasthenia Gravis and Initiation of Potential Registration Directed Randomized Phase 2 Trial

THOMSON REUTERS
·
Jun 09

TG Therapeutics - Initiates Phase 2 Trial of Briumvi as Maintenance Therapy After Efgartigimod Induction in Mg

THOMSON REUTERS
·
Jun 09

Analysts Offer Insights on Healthcare Companies: CVS Health (CVS), TG Therapeutics (TGTX) and Dexcom (DXCM)

TIPRANKS
·
Jun 04

B. Riley Securities Remains a Buy on TG Therapeutics (TGTX)

TIPRANKS
·
Jun 04

TG Therapeutics rises 10.6%

TIPRANKS
·
Jun 04